1. Home
  2. AKA vs TTRX Comparison

AKA vs TTRX Comparison

Compare AKA & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo a.k.a. Brands Holding Corp.

AKA

a.k.a. Brands Holding Corp.

HOLD

Current Price

$8.73

Market Cap

105.4M

ML Signal

HOLD

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$5.09

Market Cap

107.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKA
TTRX
Founded
2018
2015
Country
United States
United States
Employees
N/A
2
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
105.4M
107.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
AKA
TTRX
Price
$8.73
$5.09
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$24.33
$8.00
AVG Volume (30 Days)
4.7K
59.1K
Earning Date
05-12-2026
05-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$600,208,000.00
N/A
Revenue This Year
$6.14
N/A
Revenue Next Year
$4.89
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.44
N/A
52 Week Low
$8.42
$2.57
52 Week High
$16.38
$6.75

Technical Indicators

Market Signals
Indicator
AKA
TTRX
Relative Strength Index (RSI) 35.73 51.02
Support Level N/A $3.92
Resistance Level $11.42 $5.33
Average True Range (ATR) 0.48 0.55
MACD -0.11 -0.07
Stochastic Oscillator 14.90 20.44

Price Performance

Historical Comparison
AKA
TTRX

About AKA a.k.a. Brands Holding Corp.

a.k.a. Brands Holding Corp is a portfolio of fashion brands, including Princess Polly, Culture Kings, Petal & Pup, and mnml. Through these brands, the company reaches next-generation consumers who seek fashion inspiration on social media and mainly shop online. The portfolio consists of two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company generates the majority of its revenue from the United States.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: